Literature DB >> 33592583

Expression and prognostic values of ARID family members in breast cancer.

Jinfeng Zhang1, Siyu Hou1, Zilong You1, Guozheng Li1, Shouping Xu1, Xianyong Li2, Xianyu Zhang1, Bo Lei1, Da Pang1,3.   

Abstract

The ARID family is a superfamily of 15 members containing a domain that interacts with AT-rich DNA elements. However, the expression and prognostic roles of each ARID in breast cancer are still elusive. We used the TCGA and Kaplan-Meier plotter databases to assess the expression and prognostic values of ARID mRNA levels in breast cancer respectively. In the present study, 6 members were significantly lower in tumor tissues than those in the normal tissues, while 6 members were significantly higher. Further assessment of ARID expression in breast cancer with different molecular subtypes, 3 members were significantly higher in no-luminal molecular subtype than those in the luminal molecular subtype, and 6 members were significantly higher. In regard to prognostic values, high expression of ARID1A, ARID2, ARID3B, ARID4A, ARID5A, ARID5B, JARID1A were associated with favorable outcome, while ARID4B and JARID1B were correlated to a worse outcome. We further analyzed the prognostic value of ARID in different intrinsic subtypes and clinicopathological features of breast cancer. We found many meaningful ARID family biomarkers in breast cancer. The relevant results will expound the role of ARID in breast cancer and may further provide new insight to explore the ARID-targeting reagents for treating breast cancer patients.

Entities:  

Keywords:  biomarkers; breast neoplasms; prognosis; tumor

Mesh:

Substances:

Year:  2021        PMID: 33592583      PMCID: PMC7950271          DOI: 10.18632/aging.202489

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  32 in total

1.  Clinicopathological significance of ARID1B in breast invasive ductal carcinoma.

Authors:  Fei Shao; Tiantian Guo; Pei Jou Chua; Lili Tang; Aye Aye Thike; Puay-Hoon Tan; Boon Huat Bay; Gyeong Hun Baeg
Journal:  Histopathology       Date:  2015-05-17       Impact factor: 5.087

2.  Effect of screening and adjuvant therapy on mortality from breast cancer.

Authors:  Donald A Berry; Kathleen A Cronin; Sylvia K Plevritis; Dennis G Fryback; Lauren Clarke; Marvin Zelen; Jeanne S Mandelblatt; Andrei Y Yakovlev; J Dik F Habbema; Eric J Feuer
Journal:  N Engl J Med       Date:  2005-10-27       Impact factor: 91.245

3.  Recognition of an epitope of a breast cancer antigen by human antibody.

Authors:  J Cao; T Gao; A E Giuliano; R F Irie
Journal:  Breast Cancer Res Treat       Date:  1999-02       Impact factor: 4.872

4.  ARID1A and CEBPα cooperatively inhibit UCA1 transcription in breast cancer.

Authors:  Xiao Guo; Yin Zhang; Anand Mayakonda; Vikas Madan; Ling-Wen Ding; Le-Hang Lin; Saadiya Zia; Sigal Gery; Jeffrey W Tyner; Wu Zhou; Dong Yin; De-Chen Lin; H Phillip Koeffler
Journal:  Oncogene       Date:  2018-07-06       Impact factor: 9.867

5.  Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo.

Authors:  Kazuya Masuda; Barry Ripley; Riko Nishimura; Takashi Mino; Osamu Takeuchi; Go Shioi; Hiroshi Kiyonari; Tadamitsu Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-15       Impact factor: 11.205

6.  Loss of ARID1A, ARID1B, and ARID2 Expression During Progression of Gastric Cancer.

Authors:  Tatsuya Aso; Hiroshi Uozaki; Shigeki Morita; Arisa Kumagai; Masato Watanabe
Journal:  Anticancer Res       Date:  2015-12       Impact factor: 2.480

7.  Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis.

Authors:  Yu-Ching Teng; Cheng-Feng Lee; Ying-Shiuan Li; Yi-Ren Chen; Pei-Wen Hsiao; Meng-Yu Chan; Feng-Mao Lin; Hsien-Da Huang; Yen-Ting Chen; Yung-Ming Jeng; Chih-Hung Hsu; Qin Yan; Ming-Daw Tsai; Li-Jung Juan
Journal:  Cancer Res       Date:  2013-05-30       Impact factor: 12.701

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  Allelic variation and differential expression of the mSIN3A histone deacetylase complex gene Arid4b promote mammary tumor growth and metastasis.

Authors:  Scott F Winter; Luanne Lukes; Renard C Walker; Danny R Welch; Kent W Hunter
Journal:  PLoS Genet       Date:  2012-05-31       Impact factor: 5.917

10.  HuR Reduces Radiation-Induced DNA Damage by Enhancing Expression of ARID1A.

Authors:  Daniel Andrade; Meghna Mehta; James Griffith; Sangphil Oh; Joshua Corbin; Anish Babu; Supriyo De; Allshine Chen; Yan D Zhao; Sanam Husain; Sudeshna Roy; Liang Xu; Jeffrey Aube; Ralf Janknecht; Myriam Gorospe; Terence Herman; Rajagopal Ramesh; Anupama Munshi
Journal:  Cancers (Basel)       Date:  2019-12-13       Impact factor: 6.575

View more
  4 in total

1.  SARS-CoV-2 Achieves Immune Escape by Destroying Mitochondrial Quality: Comprehensive Analysis of the Cellular Landscapes of Lung and Blood Specimens From Patients With COVID-19.

Authors:  Chenyang Duan; Ruiyan Ma; Xue Zeng; Bing Chen; Dongyao Hou; Ruixue Liu; Xuehan Li; Liangming Liu; Tao Li; He Huang
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

Review 2.  Recent Advances in the Role of Arid5a in Immune Diseases and Cancer.

Authors:  Kishan Kumar Nyati; Tadamitsu Kishimoto
Journal:  Front Immunol       Date:  2022-01-19       Impact factor: 7.561

3.  Comprehensive Landscape of ARID Family Members and Their Association with Prognosis and Tumor Microenvironment in Hepatocellular Carcinoma.

Authors:  Ji Sun; Nan-Sheng Cheng
Journal:  J Immunol Res       Date:  2022-03-30       Impact factor: 4.818

4.  The Prognostic Value of AT-Rich Interaction Domain (ARID) Family Members in Patients with Hepatocellular Carcinoma.

Authors:  Siyi Li; Zhulin Wu; Qiuyue Li; Qiting Liang; Hengli Zhou; Yafei Shi; Rong Zhang; Huafeng Pan
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-18       Impact factor: 2.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.